WASHINGTON & SUNNYVALE, Calif.--(BUSINESS WIRE)--Elixir Medical, a developer of innovative drug eluting stent platforms for the treatment of cardiovascular disease, announced four-month results for EXCELLA, a first-in-man clinical trial of the company’s Novolimus™ Eluting Coronary Stent. Results were presented at the Cardiovascular Research Foundation’s (CRF) nineteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C., by Alexandre Abizaid, M.D., Ph.D., chief of Coronary Interventions at the Institute Dante Pazzanese de Cardiologia in São Paulo, Brazil.
